This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n15https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
n5http://dbpedia.org/resource/List_of_drugs:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n17https://druginfo.nlm.nih.gov/drugportal/name/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Conbercept
rdf:type
dbo:ChemicalSubstance wikidata:Q8386 n16:ChemicalObject owl:Thing dbo:Drug
rdfs:label
Conbercept
rdfs:comment
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.
dcterms:subject
dbc:Engineered_proteins dbc:Angiogenesis_inhibitors dbc:Ophthalmology_drugs
dbo:wikiPageID
66240342
dbo:wikiPageRevisionID
1105246899
dbo:wikiPageWikiLink
dbr:World_Health_Organization dbr:Placental_growth_factor dbc:Engineered_proteins dbr:Food_and_Drug_Administration dbr:Recombinant_fusion_protein dbr:Isoforms dbr:Neovascularization dbr:Anti–vascular_endothelial_growth_factor_therapy dbr:Diabetic_Macular_Edema dbr:Near-sightedness dbr:Phase_III_clinical_trials dbr:VEGF-B dbr:China_FDA dbr:Intraocular_pressure dbr:Vascular_endothelial_growth_factor dbr:Choroidal_neovascularization dbc:Ophthalmology_drugs dbr:Chengdu_Kanghong_Pharmaceutical_Group dbr:Age-related_Macular_Degeneration dbr:Kinase_insert_domain_receptor dbr:Sichuan dbr:Intravitreal_injection dbr:Mongolia dbc:Angiogenesis_inhibitors dbr:Aflibercept dbr:Syneos_Health dbr:Ranibizumab dbr:People's_Republic_of_China dbr:Polypoidal_choroidal_vasculopathy dbr:VEGF-A
dbo:wikiPageExternalLink
n17:conbercept
owl:sameAs
wikidata:Q105086385 n15:FMiCy
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Infobox_drug
dbp:casNumber
1227158
dbp:molecularWeight
142
dbp:routesOfAdministration
Intravitreal Injection
dbp:tradename
Lumitin
dbp:unii
1
dbo:abstract
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs. Conbercept was developed by Chengdu Kanghong Biotech Company in the People’s Republic of China and is marketed under the name Lumitin.
prov:wasDerivedFrom
wikipedia-en:Conbercept?oldid=1105246899&ns=0
dbo:wikiPageLength
16299
dbo:alternativeName
Lumitin
dbo:casNumber
1227158-72-6
dbo:fdaUniiCode
1P05PW62F3
foaf:isPrimaryTopicOf
wikipedia-en:Conbercept
Subject Item
dbr:Chengdu_Kanghong_Pharmaceutical_Group
dbo:wikiPageWikiLink
dbr:Conbercept
Subject Item
n5:_Cm–Co
dbo:wikiPageWikiLink
dbr:Conbercept
Subject Item
wikipedia-en:Conbercept
foaf:primaryTopic
dbr:Conbercept